Lilly, food and drug administration

US judge denies injunction, restricting copies of Lilly weight-loss drug
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.
Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs
Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, so long as the FDA considered them in shortage.
Hims & Hers down as judge denies motion over end to Lilly’s Zepbound shortage
Hims & Hers (HIMS) stock falls 8% as court denies injunction on FDA ruling for Eli Lilly's (LLY) Zepbound shortage. Read more here.
US judge ruling for FDA bars copies of Lilly weight loss drug
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S. The decision was filed late on Wednesday in response to an October lawsuit from a compounding industry group against the U.
Faced with compounded drugs, Eli Lilly tells consumers to ‘be a healthy skeptic’
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
Judge makes surprise ruling in weight-loss-drug case
Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues. The San Francisco telehealth company could've used some strong medicine on March 6 when its shares took sick amid a court ruling and stepped up competition involving weight-loss drugs.
Lilly offers weight-loss drugs in vials at a discount to fight competition
Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from compounding pharmacies and rival Novo Nordisk .
Compounders must stop making copies of Eli Lilly’s weight loss drugs: Judge
Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.
Fierce Pharma2d
Texas court decision prevents compounders from producing knockoffs of Eli Lilly's tirzepatide
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
BioSpace3d
Novo Enters the Ring in Legal Fight Against GLP-1 Compounders as Lilly Notches Victory
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
Verywell Health on MSN8d
Eli Lilly Lowers Cost of Zepbound Vials to Attract People Without Insurance Coverage
Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...
Fierce Pharma4d
Lilly's first DTC Ebglyss campaign highlights eczema’s effects on a range of skin tones and age groups
After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...
InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Fierce Healthcare2d
Eli Lilly expands telehealth access to low-cost Zepbound with Teladoc Health, LifeMD tie-ups
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
pharmaphorum21h
FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney disease
The FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new use, to reduce the risk of renal failure and cardiovascular death in people with chronic ...
STAT2d
Judge rules against compounding group; Hims’ shares fall
From STAT’s Elaine Chen: A federal judge this week ruled against a compounding trade group that wanted to continue making ...